Having completed the clinical validation of its ATScan test for autism spectrum disorder, CombiMatrix last month announced that it would make the technology available through its CLIA labs.
CombiMatrix said that the launch of the microarray-based test is timely since it follows the American Academy of Pediatrics’ recently updated guidelines recommending all children be screened at least twice for autism before the age of two.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
